The Amyloidosis Channel on VJHemOnc is an independent medical education platform, supported with funding from Prothena (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISH 2022 | Current status & updates in the management of AL amyloidosis
Meral Beksac, MD, Ankara University, Ankara, Turkey, gives an update on the current status and latest findings in the amyloidosis space. Although the path to fully diagnose a patient is long, a multidisciplinary approach that considers all symptoms, in particular cardiovascular, is helping to reach a diagnosis earlier. In addition, the correct identification of the type of amyloidosis guides physicians to better treatment decisions. In particular, the ANDROMEDA trial (NCT03201965) has recently proven the efficacy of daratumumab in combination with cyclophosphamide, bortezomib, and dexamethasone (CyBorD) in patients with amyloid light-chain (AL) amyloidosis. This interview took place at the 38th World Congress of the International Society of Hematology (ISH) 2022.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
